Virchows Archiv

, Volume 464, Issue 3, pp 333–346

Prognostic biomarkers in thyroid cancer

Authors

    • Institute of Molecular Pathology and Immunology of University of Porto (IPATIMUP)
    • Department of Pathology and Oncology, Faculty of MedicineUniversity of Porto
  • Ricardo Celestino
    • Institute of Molecular Pathology and Immunology of University of Porto (IPATIMUP)
  • Miguel Melo
    • Institute of Molecular Pathology and Immunology of University of Porto (IPATIMUP)
    • Faculty of MedicineUniversity of Coimbra
    • Department of Endocrinology, Diabetes and MetabolismUniversity and Hospital Center of Coimbra
  • Elsa Fonseca
    • Institute of Molecular Pathology and Immunology of University of Porto (IPATIMUP)
    • Department of Pathology and Oncology, Faculty of MedicineUniversity of Porto
    • Department of PathologyHospital São João
  • Manuel Sobrinho-Simões
    • Institute of Molecular Pathology and Immunology of University of Porto (IPATIMUP)
    • Department of Pathology and Oncology, Faculty of MedicineUniversity of Porto
    • Department of PathologyHospital São João
Invited Review

DOI: 10.1007/s00428-013-1521-2

Cite this article as:
Soares, P., Celestino, R., Melo, M. et al. Virchows Arch (2014) 464: 333. doi:10.1007/s00428-013-1521-2

Abstract

Thyroid carcinomas represent a challenging problem from the prognostic standpoint. Despite an overall good prognosis of the most frequent endocrine malignancy, 10–15 % of papillary thyroid carcinomas (PTCs) turn refractory to radioactive iodine therapy. The increased incidence of thyroid cancer has led to the search for solid prognostic biomarkers that predict the behaviour of these tumours. Clinical and histopathological prognostic factors remain the only safe elements to be used for diagnosis and prognosis of patients with thyroid tumours. Despite the huge amount of genetic information of thyroid tumours, very few new markers revealed diagnostic or prognostic value per se. BRAF mutation can have some value if associated to other clinico-pathological parameters, or in the particular setting of iodine refractory tumours. Others can prove interesting in the future as predictive biomarkers of therapeutic response, but more studies are needed to confirm these potential biomarkers.

Keywords

ThyroidCancerBiomarkerPrognostic

Copyright information

© Springer-Verlag Berlin Heidelberg 2014